Inhibrx Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 73.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.08B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc...